Company: HROW
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001641172-25-009263
Chunk: 2

Company: HARROW, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Item 1
Chunk 2
---
 of sales 
     (15,524,000) 
     (10,553,000)
  
    Gross profit 
     32,307,000  
     24,034,000 
  
    Operating expenses: 

    Selling, general and administrative 
     40,513,000  
     28,813,000 
  
    Research and development 
     3,026,000  
     2,149,000 
  
    Total operating expenses 
     43,539,000  
     30,962,000 
  
    Loss from operations 
     (11,232,000) 
     (6,928,000)
  
    Other (expense) income: 

    Interest expense, net 
     (6,548,000) 
     (5,415,000)
  
    Investment loss from Eton Pharmaceuticals 
     -  
     (1,248,000)
  
    Other income, net 
     -  
     26,000 
  
    Total other expense, net 
     (6,548,000) 
     (6,637,000)
  
    Net loss 
     (17,780,000) 
     (13,565,000)
  
    Basic and diluted net loss per share of common stock 
    $(0.50) 
    $(0.38)
  
    Weighted average number of shares of common stock
    outstanding, basic and diluted 
     35,826,452  
     35,469,638 

The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements

 4 

HARROW, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF STOCKHOLDERS’ EQUITY

For the Three Months Ended March 31,
2025 and 2024

    Total  
    Total  

    Common Stock  
    Additional  
       
    Harrow, Inc.  
    Noncontrolling  
    Total 

    Par  
    Paid-in  
    Accumulated  
    Stockholders’  
    Interest  
    Stockholders’ 

    Shares  
    Value  
    Capital  
    Deficit  
    Equity  
    Equity  
    Equity 
  
    Balance at January 1, 2024